Search - tctmd.com

Displaying 421 - 440 of 1179

Sort: Relevancy | Date

Presentation TCT 2015

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies Focused Commentary

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, Roxana Mehran

October 12, 2015

Presentation TCT 2015

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, Marco Valgimigli

October 12, 2015

Presentation TCT 2015

DAPT Duration After DES: Does 1 Size Fit All? Focused Commentary

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, John A. Bittl

October 12, 2015

Presentation TCT 2015

DAPT Duration After DES: Does 1 Size Fit All?

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, John A. Bittl

October 12, 2015

News Conference News TCT 2015

DAPT Study Subanalysis Focuses on EES Subgroup

October 12, 2015

News Conference News TCT 2015

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

October 12, 2015

News Conference News TCT 2015

Very Late Stent Thrombosis Remains an Important Clinical Target

October 12, 2015

News Conference News TCT 2015

Despite Setbacks, Research Into Myocardial Salvage Continues

October 12, 2015

News Opinion Fellow Talk

Researcher Much? A Brief Review of TCT’s Clinical Trial Design and Interpretation Sessions

October 11, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Industry News

Tamir Wolf, MD, PhD Joins the Cardiovascular Research Foundation as Senior Director, Operations and Development for the CRF Clinical Trials Center

October 08, 2015

News Industry News

MyoKardia Provides Update on Two Phase 1 Trials of MYK-461 for the Treatment of Hypertrophic Cardiomyopathy

October 07, 2015

News Daily News

Transradial PCI May Attenuate Bivalirudin Benefits

Todd Neale

October 05, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Extended Follow-Up Of ANTHEM-HF Patients Shows That Benefits Of Autonomic Regulation Therapy Are Maintained After 12 Months

September 28, 2015

News Daily News

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

L.A. McKeown

September 21, 2015

News Daily News

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

Yael L. Maxwell

September 18, 2015

News Industry News

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

September 16, 2015

News Industry News

Laguna Pharmaceuticals Initiates Phase 3 Study of Vanoxerine in Atrial Fibrillation and Atrial Flutter

September 14, 2015

News Industry News

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

September 11, 2015

Advertisement

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies Focused Commentary

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies

DAPT Duration After DES: Does 1 Size Fit All? Focused Commentary

DAPT Duration After DES: Does 1 Size Fit All?

DAPT Study Subanalysis Focuses on EES Subgroup

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

Very Late Stent Thrombosis Remains an Important Clinical Target

Despite Setbacks, Research Into Myocardial Salvage Continues

Researcher Much? A Brief Review of TCT’s Clinical Trial Design and Interpretation Sessions

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Tamir Wolf, MD, PhD Joins the Cardiovascular Research Foundation as Senior Director, Operations and Development for the CRF Clinical Trials Center

MyoKardia Provides Update on Two Phase 1 Trials of MYK-461 for the Treatment of Hypertrophic Cardiomyopathy

Transradial PCI May Attenuate Bivalirudin Benefits

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Extended Follow-Up Of ANTHEM-HF Patients Shows That Benefits Of Autonomic Regulation Therapy Are Maintained After 12 Months

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

Laguna Pharmaceuticals Initiates Phase 3 Study of Vanoxerine in Atrial Fibrillation and Atrial Flutter

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content